Anxiety DisordersPMAXNCT06016907
Stepped vs Stratified Care for Pediatric Anxiety Disorders
A study testing Internet-delivered cognitive behavioral therapy (ICBT) and In-person cognitive behavioral therapy (CBT) in people with Anxiety Disorders, run by Region Skane at 1 site in Sweden.
Trial summary
The purpose of this trial is to evaluate the feasibility, acceptability, and safety of two care pathways (including internet-delivered cognitive behavioral therapy [CBT] and/or in-person CBT) for children and adolescents with anxiety disorders. Read more about this study
- Who is it for?
- Ages 8 to 17 years
- Conditions the study is for
- Anxiety Disorders
- What is being tested?
- Internet-delivered cognitive behavioral therapy (ICBT) and In-person cognitive behavioral therapy (CBT)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 51 participants
- Where
- 1 siteSweden
- Study dates
- 2 Oct 2023to 14 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- 8 to <18 years of age.
- A principal Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) anxiety disorder of social anxiety disorder, generalized anxiety disorder, panic disorder, separation anxiety disorder, specific phobia, or agoraphobia.
- A Clinical Global Impression Scale - Severity (CGI-S) score >3 in relation to severity of all anxiety symptoms.
- Child and caregiver able to read, write and communicate in Swedish.
- An available caregiver who can support the child in treatment.
- Access to the internet.
- Ability to attend treatment sessions at the clinic.
Who cannot join
- Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises).
- Established or suspected intellectual disability.
- Another mental disorder in more immediate need of management than an anxiety disorder (e.g., schizophrenia spectrum and other psychotic disorders, bipolar disorder, anorexia nervosa, substance use disorders).
- Social/familial/educational difficulties in more immediate need of management than an anxiety disorder.
- Ongoing psychological treatment for an anxiety disorder.
- Initiation or adjustment of any psychotropic medication for anxiety (i.e., selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitor or antipsychotics) within 8 weeks prior to assessment.
- Immediate risk to self or others that require urgent attention, such as suicidality.
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Child and Adolescent Mental Health Services, Region Skane
Lund, Skåne County, 22185
About this study
Official title: A Pilot Randomized Controlled Trial of Stepped vs Stratified Care for Pediatric Anxiety Disorders
The purpose of this trial is to evaluate the feasibility, acceptability, and safety of two care pathways (including internet-delivered cognitive behavioral therapy [CBT] and/or in-person CBT) for children and adolescents with anxiety disorders.
Read the detailed description
Introduction: Anxiety disorders are a major contributor to disability in children and adolescents. Cognitive behavioral therapy (CBT), delivered both in-person and by the internet (ICBT), is efficacious, but how to best organize the care pathway to increase access and benefit is unclear.
Methods: With the aim to conduct a fully powered randomized controlled trial, the present study is a randomized controlled, single-blind, pilot study where 50 youth with anxiety disorders and their caregivers will be randomized (1:1) to stepped care or stratified care. Stepped and stratified care are two competing service delivery models which include evidence-based interventions but differ regarding the timing and staging of interventions.
In the stepped care arm, all participants will begin with 12 modules of ICBT delivered over 12 weeks. Participants with an insufficient response will then be offered 12-weeks of personalized in-person CBT. In the stratified care arm, the investigators aim to offer about half of the participants ICBT and the other half in-person CBT, with this selection being based on a risk score algorithm that integrates known predictors of non-response to treatment.
Mirroring the structure in stepped care, all non-responders in stratified care (both those who started with ICBT and in-person CBT) will be offered an additional 12-week course of in-person CBT. The ICBT and in-person CBT interventions will be identical in treatment length, but will differ in the delivery of treatment, utilizing the possibility of increased personalization and therapist-involvement in in-person CBT.
The objectives of the pilot study are to examine feasibility, acceptability, and safety of study procedures, precision of the risk score algorithm, and statistical properties of outcome measures. The feasibility, acceptability, and safety objectives are operationalized in detail in the full study protocol published at the Open Science Framework (OSF; see link in the References-section at the bottom of this record).
Data will be collected at baseline, post-allocation (week 1), weekly during treatment course A (week 2-13), after treatment course A (POST-1; time window for data collection between week 14-17), weekly during treatment course B (if applicable, week 18-29), and after treatment course B (POST-2; time window for data collection between week 30-33). POST-2 is the primary endpoint of the study.
- Conditions
- Anxiety Disorders
- Being tested
- Internet-delivered cognitive behavioral therapy (ICBT), In-person cognitive behavioral therapy (CBT)
- Keywords
- Anxiety Disorders, Children, Adolescents, Cognitive behavioral therapy, RCT, Care pathway, Stepped care, Stratified care
- Medical subject headings
- Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Internet-delivered cognitive behavioral therapy (ICBT)Behavioural
Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
In-person cognitive behavioral therapy (CBT)Behavioural
Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
| Study group | Role | What they receive |
|---|---|---|
| Stepped care | Other | Participants will receive up to two courses of treatment. All participants in stepped care will receive internet-delivered cognitive behavioral therapy (ICBT) in the first course (A). Participants with an insufficient treatment response will then be offered in-person cognitive behavioral therapy (CBT) in the second course (B). Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments. Receives: Behavioral: Internet-delivered cognitive behavioral therapy (ICBT); Behavioral: In-person cognitive behavioral therapy (CBT) |
| Stratified care | Other | Participants will receive up to two courses of treatment. In stratified care, in treatment course A, the investigators aim to offer around half of the participants ICBT and the other half in-person CBT (based on their risk of non-response). All participants in stratified care who do not sufficiently respond to treatment in course A will be offered personalized in-person CBT in course B. Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments. Receives: Behavioral: Internet-delivered cognitive behavioral therapy (ICBT); Behavioral: In-person cognitive behavioral therapy (CBT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pediatric Anxiety Rating Scale (PARS)
Used to assess anxiety severity. Clinician-rated. Primary clinical outcome of the study. The scale yields a score of 0 to 35, with higher scores indicating more severe anxiety.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Secondary outcomes (35)
Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
Used to assess anxiety disorders and psychiatric comorbidity at baseline and anxiety disorders and major depression at follow-ups. Clinician-rated.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Clinical Global Impression Scale - Severity (CGI-S)
Used to assess overall anxiety severity. Clinician-rated. Ratings are reported on a seven-graded scale from 1 ("Normal, not at all ill") to 7 ("Among the most extremely ill patients").
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Clinical Global Impression Scale - Improvement (CGI-I)
Used to assess level of improvement compared to admission. Clinician-rated. This single item scale ranges from 1 ("Very much improved") to 7 ("Very much worse").
Measured: POST-1 (week 14-17); POST-2 (week 30-33).
Children's Global Assessment Scale (CGAS)
Used to assess global impairment. Clinician-rated. The CGAS is a single item scale that ranges from 1 to 100, with a higher value indicating better functioning.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Number of participants with concomitant interventions
Used to assess potential other treatments during the study period. Clinician-rated.
Measured: POST-1 (week 14-17); POST-2 (week 30-33).
Measure of accidental unmasking
Used to assess the number of occasions where outcome assessors are accidentally unmasked to group allocation.
Measured: POST-1 (week 14-17); POST-2 (week 30-33).
Guess of group allocation
Used to assess the percentage of correctly guessed group allocation from masked outcome assessors.
Measured: POST-1 (week 14-17); POST-2 (week 30-33).
Experiences of participating in the study
A semi-structured interview conducted by a non-masked study coordinator covering (i) burden of participation, (ii) experiences of interventions, (iii) understandability of measures/interviews, and (iv) missing content in measures/interviews. Clinician-rated.
Measured: POST-2 (week 30-33).
Interviews with participants about treatment
A semi-structured interview conducted by a non-masked researchers who is not otherwise involved in the study covering topics about treatment content, treatment timing, degree of therapist contact, caregiver collaboration and personal effort/motivation as well as themes important to the child/adolescent. Clinician-rated.
Measured: POST-1 (week 14-17) or POST-2 (week 30-33).
Revised Child Anxiety and Depression Scale - Child version (RCADS-C)
Used to assess anxiety symptoms. Child/adolescent-reported. The RCADS version used in the present study is the 47-item version which ranges from 0 to 141 points, with higher scores indicating more severe internalizing symptoms.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Child Anxiety Life Interference Scale - Revised - Child version (CALIS-R-C)
Used to assess life interference and impairment associated with childhood anxiety. The scale ranges from 0 to 36 points, with higher scores indicating higher interference and impairment.Child/adolescent-reported.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Deliberate Self-harm Inventory - Youth version (DSHI-Y)
Used to assess self-harm. Child/adolescent-reported.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Ill temper scale of the Inventory of Depression and Anxiety Symptoms II - Child version (IDAS-II-C)
Used to assess irritability. Child/adolescent-reported. The scale ranges from 0 to 20 points, with higher scores indicating greater anger.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Child Health Utility 9D (CHU9D)
Used to assess health-related quality of life. Child/adolescent-reported. The scale ranges from 9 to 45 points, with higher scores indicating worse quality of life.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Systematic Clinical Outcome and Routine Evaluation-15 - Child version (SCORE-15-C)
Used to assess family functioning. Child/adolescent-reported. The scale ranges from 15 to 75, with a lower score indicating higher family functioning.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Need for treatment - Child version
Used to assess need of treatment for anxiety symptoms. Child/adolescent-reported. This single item scale ranges from 1 to 5 points, with higher scores indicating a higher need for treatment.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Client Satisfaction Questionnaire - Child version (CSQ-8-C)
Used to assess treatment satisfaction. Child/adolescent-reported. The scale ranges from 9 to 36 points, with higher scores indicating greater satisfaction.
Measured: POST-1 (week 14-17); POST-2 (week 30-33; only if a second round of treatment is initiated).
Adverse events questionnaire - Child version (AEQ-C)
Used to assess adverse events/effects. Child/adolescent-reported. The scale consists of 22 yes/no items (score range 0-22 points) with higher scores indicating more present adverse events. For each adverse event that is present, there is also a rating of whether the adverse event is thought to be related to the provided treatment (yes or no).
Measured: Every third week during week 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Working alliance - Child version
Used to assess the participant's perceived working alliance with their therapist. Child/adolescent-reported. The scale ranges from 0 to 36 points, with higher scores indicating better working alliance.
Measured: Every third week during weeks 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Revised Child Anxiety and Depression Scale - Parent version (RCADS-P)
Used to assess anxiety symptoms. Caregiver-reported. The RCADS version used in the present study is the 47-item version which ranges from 0 to 141 points, with higher scores indicating more severe internalizing symptoms.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Child Anxiety Life Interference Scale - Revised - Parent version (CALIS-R-P)
Used to assess life interference and impairment associated with childhood anxiety. Caregiver-reported. The scale ranges from 0 to 36 points, with higher scores indicating higher interference and impairment.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Systematic Clinical Outcome and Routine Evaluation-15 - Parent version (SCORE-15-P)
Used to assess family functioning. Caregiver-reported. The scale ranges from 15 to 75, with a lower score indicating higher family functioning.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Ill temper scale of the Inventory of Depression and Anxiety Symptoms II - Parent version (IDAS-II-P)
Used to assess irritability. Caregiver-reported. The scale ranges from 0 to 20 points, with higher scores indicating greater anger.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Need for treatment - Parent version
Used to assess need of treatment for anxiety symptoms. Caregiver-reported. This single item scale ranges from 1 to 5 points, with higher scores indicating a higher need for treatment.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
The Treatment Inventory of Costs in Patients With Psychiatric Disorders (TIC-P)
Used to assess healthcare and other societal resource use for both children and caregivers. Caregiver-reported.
Measured: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Client Satisfaction Questionnaire - Parent version (CSQ-8-P)
Used to assess treatment satisfaction. Caregiver-reported. The scale ranges from 9 to 36 points, with higher scores indicating greater satisfaction.
Measured: POST-1 (week 14-17); POST-2 (week 30-33; only if a second round of treatment is initiated).
Adverse events questionnaire - Parent version (AEQ-P)
Used to assess adverse events/effects. Parent-reported. The scale consists of 22 yes/no items (score range 0-22 points) with higher scores indicating more present adverse events. For each adverse event that is present, there is also a rating of whether the adverse event is thought to be related to the provided treatment (yes or no).
Measured: Every third week during week 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Working alliance - Parent version
Used to assess the caregiver's perceived working alliance with their therapist. Caregiver-reported. The scale ranges from 0 to 36 points, with higher scores indicating better working alliance.
Measured: Every third week during weeks 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Behavioral, Emotional, and Social Skills Inventory (BESSI)
Used to assess emotional resilience and self-management. Child/adolescent and caregiver-reported. The scale consists of 102 items, each rated from 1 to 5 points, and scores are presented as averages on six different combinations of items, referred to as "Skill domains".
Measured: Week 1; POST-2 (week 30-33).
The PROMIS peer relationships short form (PR-SF)
Used to assess peer relationships. Child/adolescent-reported. The scale ranges from 8 to 40 points, with higher scores indicating greater peer relationships.
Measured: Week 1; POST-2 (week 30-33).
Avoidance and Fusion Questionnaire for Youth (AFQ-Y8)
Used to assess psychological inflexibility. Child/adolescent-reported. The scale ranges from 0 to 32 points, with higher scores indicating greater psychological inflexibility.
Measured: Week 1; POST-2 (week 30-33).
The Cognitive-attentional Syndrome Questionnaire (CAS-1)
Used to assess dysfunctional metacognitive beliefs. Child/adolescent-reported. The questionnaire consists of four domains. Each item of the three first domains is scored on a 0-8 point scale. Each item of the fourth domain is score on 0-100 scale. Higher scores indicates more dysfunctional metacognitive beliefs.
Measured: Week 1; POST-2 (week 30-33).
Hierarchical Personality Inventory for Children (HiPIC-30)
Used to assess personality traits. Child/adolescent and caregiver-reported. The questionnaire collects data on five personality domains. Each of the 30 items range from 1 to 5 points. Higher scores indicates greater indication of the personality domain in question.
Measured: Week 1.
Swanson, Nolan, and Pelham Rating Scale (SNAP-IV)
Used to assess attention difficulties, hyperactivity, impulsivity, and oppositional symptoms. Caregiver-reported. Each item is scored from 0 to 3 points. The item scores are then summarized in domains: inattention (items 1-9), hyperactivity-impulsivity (items 11-19) and oppositional (items 21-28). Items 10, 20 and 29 are not included in any of the domains. Higher scores indicate greater attention difficulties, hyperactivity, impulsivity, and oppositional symptoms.
Measured: Week 1; POST-2 (week 30-33).
Autism Phenotype Scale (APS)
Used to assess core autism traits. Child/adolescent and caregiver-reported. The scale ranges from 0 to 36 points, with higher scores indicating greater autism traits.
Measured: Week 1; POST-2 (week 30-33).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2023
- Study start2 Oct 2023
- Primary completion30 Oct 2024
- Study completion14 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anxiety DisordersStudies of the same condition, open and under way.
- More trials run by Region SkaneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A pilot, single-blind, parallel-group (2 groups), randomized controlled trial for children and adolescents with anxiety disorders. Participants will be randomized at a 1:1 ratio to one out of two care pathways: stepped care and stratified care. Each care pathway consists of up to two courses of treatment.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Region Skane
- Sponsor type
- University, hospital or other
- Collaborators
- Lund University
- Responsible party
- Sponsor
- Investigators
- Eva Serlachius, MD, PhD, Principal investigator, Region Skane and Lund University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06016907
- Sponsor's protocol ID
- 2022-07219-01
- Acronym
- PMAX
- Status last verified
- Nov 2024
- First submitted
- 16 Aug 2023
- Last updated
- 27 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The data are pseudonymized according to national (Swedish) and European Union legislation and cannot be anonymised and published in an open repository. Participants in the study consent for their data to be shared with other international researchers for research purposes. The data can be made available upon reasonable request on a case-by-case basis according to the current legislation and ethical permits.
Study at a glance
From the registry record, last updated by the sponsor on 27 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Randomized Controlled Trial of Stepped vs Stratified Care for Pediatric Anxiety Disorders
- ClinicalTrials.gov ID
- NCT06016907
- Acronym / sponsor ID
- PMAX / 2022-07219-01
- Conditions
- Anxiety Disorders
- Keywords
- Anxiety Disorders, Children, Adolescents, Cognitive behavioral therapy, RCT, Care pathway, Stepped care, Stratified care
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Region SkaneUniversity, hospital or other
- Collaborators
- Lund University
- Study start
- 2 Oct 2023 (actual)
- Primary completion
- 30 Oct 2024 (actual)
- Study completion
- 14 Nov 2024 (actual)
- First posted
- 30 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this trial is to evaluate the feasibility, acceptability, and safety of two care pathways (including internet-delivered cognitive behavioral therapy [CBT] and/or in-person CBT) for children and adolescents with anxiety disorders.
Detailed description
Introduction: Anxiety disorders are a major contributor to disability in children and adolescents. Cognitive behavioral therapy (CBT), delivered both in-person and by the internet (ICBT), is efficacious, but how to best organize the care pathway to increase access and benefit is unclear.
Methods: With the aim to conduct a fully powered randomized controlled trial, the present study is a randomized controlled, single-blind, pilot study where 50 youth with anxiety disorders and their caregivers will be randomized (1:1) to stepped care or stratified care. Stepped and stratified care are two competing service delivery models which include evidence-based interventions but differ regarding the timing and staging of interventions.
In the stepped care arm, all participants will begin with 12 modules of ICBT delivered over 12 weeks. Participants with an insufficient response will then be offered 12-weeks of personalized in-person CBT. In the stratified care arm, the investigators aim to offer about half of the participants ICBT and the other half in-person CBT, with this selection being based on a risk score algorithm that integrates known predictors of non-response to treatment.
Mirroring the structure in stepped care, all non-responders in stratified care (both those who started with ICBT and in-person CBT) will be offered an additional 12-week course of in-person CBT. The ICBT and in-person CBT interventions will be identical in treatment length, but will differ in the delivery of treatment, utilizing the possibility of increased personalization and therapist-involvement in in-person CBT.
The objectives of the pilot study are to examine feasibility, acceptability, and safety of study procedures, precision of the risk score algorithm, and statistical properties of outcome measures. The feasibility, acceptability, and safety objectives are operationalized in detail in the full study protocol published at the Open Science Framework (OSF; see link in the References-section at the bottom of this record).
Data will be collected at baseline, post-allocation (week 1), weekly during treatment course A (week 2-13), after treatment course A (POST-1; time window for data collection between week 14-17), weekly during treatment course B (if applicable, week 18-29), and after treatment course B (POST-2; time window for data collection between week 30-33). POST-2 is the primary endpoint of the study.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- A pilot, single-blind, parallel-group (2 groups), randomized controlled trial for children and adolescents with anxiety disorders. Participants will be randomized at a 1:1 ratio to one out of two care pathways: stepped care and stratified care. Each care pathway consists of up to two courses of treatment.
| Arm | Type | Receives |
|---|---|---|
| Stepped care | Other | Behavioral: Internet-delivered cognitive behavioral therapy (ICBT), Behavioral: In-person cognitive behavioral therapy (CBT)Participants will receive up to two courses of treatment. All participants in stepped care will receive internet-delivered cognitive behavioral therapy (ICBT) in the first course (A). Participants with an insufficient treatment response will then be offered in-person cognitive behavioral therapy (CBT) in the second course (B). Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments. |
| Stratified care | Other | Behavioral: Internet-delivered cognitive behavioral therapy (ICBT), Behavioral: In-person cognitive behavioral therapy (CBT)Participants will receive up to two courses of treatment. In stratified care, in treatment course A, the investigators aim to offer around half of the participants ICBT and the other half in-person CBT (based on their risk of non-response). All participants in stratified care who do not sufficiently respond to treatment in course A will be offered personalized in-person CBT in course B. Even if participants are offered treatment in course B, participants are free to decline this offer, and will instead only be invited to the remaining outcome assessments. |
Who may qualify
- Ages
- 8 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (7 listed)
- 8 to <18 years of age.
- A principal Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) anxiety disorder of social anxiety disorder, generalized anxiety disorder, panic disorder, separation anxiety disorder, specific phobia, or agoraphobia.
- A Clinical Global Impression Scale - Severity (CGI-S) score >3 in relation to severity of all anxiety symptoms.
- Child and caregiver able to read, write and communicate in Swedish.
- An available caregiver who can support the child in treatment.
Key exclusion criteria (7 listed)
- Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises).
- Established or suspected intellectual disability.
- Another mental disorder in more immediate need of management than an anxiety disorder (e.g., schizophrenia spectrum and other psychotic disorders, bipolar disorder, anorexia nervosa, substance use disorders).
- Social/familial/educational difficulties in more immediate need of management than an anxiety disorder.
- Ongoing psychological treatment for an anxiety disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Internet-delivered cognitive behavioral therapy (ICBT)Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support. | Behavioural | Stepped care, Stratified care |
| In-person cognitive behavioral therapy (CBT)Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist. | Behavioural | Stepped care, Stratified care |
Primary outcome
Pediatric Anxiety Rating Scale (PARS)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Used to assess anxiety severity. Clinician-rated. Primary clinical outcome of the study. The scale yields a score of 0 to 35, with higher scores indicating more severe anxiety.
35 secondary outcomes
Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Clinical Global Impression Scale - Severity (CGI-S)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Clinical Global Impression Scale - Improvement (CGI-I)
Time frame: POST-1 (week 14-17); POST-2 (week 30-33).
Children's Global Assessment Scale (CGAS)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Number of participants with concomitant interventions
Time frame: POST-1 (week 14-17); POST-2 (week 30-33).
Measure of accidental unmasking
Time frame: POST-1 (week 14-17); POST-2 (week 30-33).
Guess of group allocation
Time frame: POST-1 (week 14-17); POST-2 (week 30-33).
Experiences of participating in the study
Time frame: POST-2 (week 30-33).
Interviews with participants about treatment
Time frame: POST-1 (week 14-17) or POST-2 (week 30-33).
Revised Child Anxiety and Depression Scale - Child version (RCADS-C)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Child Anxiety Life Interference Scale - Revised - Child version (CALIS-R-C)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Deliberate Self-harm Inventory - Youth version (DSHI-Y)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Ill temper scale of the Inventory of Depression and Anxiety Symptoms II - Child version (IDAS-II-C)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Child Health Utility 9D (CHU9D)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Systematic Clinical Outcome and Routine Evaluation-15 - Child version (SCORE-15-C)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Need for treatment - Child version
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Client Satisfaction Questionnaire - Child version (CSQ-8-C)
Time frame: POST-1 (week 14-17); POST-2 (week 30-33; only if a second round of treatment is initiated).
Adverse events questionnaire - Child version (AEQ-C)
Time frame: Every third week during week 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Working alliance - Child version
Time frame: Every third week during weeks 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Revised Child Anxiety and Depression Scale - Parent version (RCADS-P)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Child Anxiety Life Interference Scale - Revised - Parent version (CALIS-R-P)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Systematic Clinical Outcome and Routine Evaluation-15 - Parent version (SCORE-15-P)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Ill temper scale of the Inventory of Depression and Anxiety Symptoms II - Parent version (IDAS-II-P)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Need for treatment - Parent version
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
The Treatment Inventory of Costs in Patients With Psychiatric Disorders (TIC-P)
Time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).
Client Satisfaction Questionnaire - Parent version (CSQ-8-P)
Time frame: POST-1 (week 14-17); POST-2 (week 30-33; only if a second round of treatment is initiated).
Adverse events questionnaire - Parent version (AEQ-P)
Time frame: Every third week during week 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Working alliance - Parent version
Time frame: Every third week during weeks 2-13 and 18-29 (the latter applies only if a second round of treatment is initiated).
Behavioral, Emotional, and Social Skills Inventory (BESSI)
Time frame: Week 1; POST-2 (week 30-33).
The PROMIS peer relationships short form (PR-SF)
Time frame: Week 1; POST-2 (week 30-33).
Avoidance and Fusion Questionnaire for Youth (AFQ-Y8)
Time frame: Week 1; POST-2 (week 30-33).
The Cognitive-attentional Syndrome Questionnaire (CAS-1)
Time frame: Week 1; POST-2 (week 30-33).
Hierarchical Personality Inventory for Children (HiPIC-30)
Time frame: Week 1.
Swanson, Nolan, and Pelham Rating Scale (SNAP-IV)
Time frame: Week 1; POST-2 (week 30-33).
Autism Phenotype Scale (APS)
Time frame: Week 1; POST-2 (week 30-33).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Nov 2024.
- All full study protocol versions are available at this open repository.Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided. The data are pseudonymized according to national (Swedish) and European Union legislation and cannot be anonymised and published in an open repository. Participants in the study consent for their data to be shared with other international researchers for research purposes. The data can be made available upon reasonable request on a case-by-case basis according to the current legislation and ethical permits.
Related trials for Anxiety Disorders
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eva Serlachius, MD, PhD principal investigator
Region Skane and Lund University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Internet-delivered cognitive behavioral therapy (ICBT) and In-person cognitive behavioral therapy (CBT) in people with Anxiety Disorders, run by Region Skane at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pediatric Anxiety Rating Scale (PARS) (time frame: Baseline; POST-1 (week 14-17); POST-2 (week 30-33).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Nov 2024.